摘要
达拉菲尼是一种靶向BRAF激酶抑制剂,美国食品和药物管理局批准用于治疗转移性黑色素瘤和不能行手术治疗的黑色素瘤患者。本文对达拉菲尼的合成路线、作用机制、药动学特征、临床疗效、药物相互作用、药物不良反应及联合用药等作一综述。
Dabrafenib is a target BRAF kinase inhibitor. The U.S. Food and Drug Administration approved dabrafenib as single-agent therapies for the treatment of metastatic melanoma. The synthetic route, the mechanism of action, the pharmacokinetic and pharmacodynamic properties, the clinical efficacy, the drug interactions together, the adverse drug reaction and the drug combination are reviewed in this article.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2014年第11期785-787,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
达拉菲尼
黑色素瘤
抗肿瘤药
dabrafenib
melanoma
antineoplastic agents
